|
|
ASH 2006 Highlights for Patients with Myeloma
By Lynne Lederman, PhD
The landscape of multiple myeloma treatment continues to evolve as research results accumulate from trials of conventional and new therapies and from studies on risk factors and side effects. The IMF brings you highlights of the 48th Annual Meeting of the American Society of Hematology.
|
|
Overview of ASH 2006 in Czech
Ein Überblick über den ASH-Kongress
Overview of ASH 2006 in Hebrew
A Randomized Study of Lenalidomide with High- or Low-Dose Dexamethasone in the Treatment of Newly Diagnosed Myeloma
An International Randomized Trial of Thal/Dex vs Dexamethasone Alone
An Overview of Planned Randomized Clinical Trials for Newly Diagnosed Younger and Older Patients in Spain
Analysis of Phase III Study of Revlimid + Dexamethasone in Patients >65 Years
Breaking the Plateau Response in MM: Results of a Pilot Study of Vel/Dex/Doxil (DoVeD)
Identification of Mutations in the NFkB Pathway That Predict Velcade Response
Long Term Results of a Study of Rev/Dex in Newly Diagnosed Patients
Long-Term Follow-Up of a Phase II Trial of Vel/Dex in Frontline Therapy for Myeloma
Phase I/II Study of Revlimid + Melphalan/Prednisone (R-MP) for Newly Diagnosed Myeloma
Relationship Between Quality of Response to Velcade and Clinical Benefit
Revlimid-Induced Myelosuppression is Potentially Associated with Renal Dysfunction in Treatment-Naïve MM Patients Receiving BiRD
The Use of Lenalidomide +/- Dexamethasone in Patients with AL Amyloidosis
The Use of Velcade + Melphalan/Prednisone in Elderly Non-Transplant Patients
The Use of Velcade as First-Line Therapy in High-Risk Myeloma
Use of Revlimid With or Without Steroids in Relapsed/Refractory Myeloma Patients with Elevated Baseline Serum Creatinine
Velcade and Doxil as Induction Therapy for Newly Diagnosed Myeloma
A Phase I/II Study of Revlimid, Adriamycin, and Dexamethasone (RAD) in Patients with Relapsed/Refractory Myeloma
A Phase II Study of Velcade, Doxil, and Thalidomide (VDT) in Relapsed/Refractory Myeloma
A Subset Study of Lenalidomide/Dexamethasone vd Dexamethasone Alone After Thalidomide Therapy in Relapsed/Refractory Myeloma
Amplification of 1q21 Is Associated with Poor Outcome after Treatment with Bortezomib in Relapsed/Refractory Multiple Myeloma
Combination of Revlimid and Velcade in the Treatment of Relapsed/Refractory Myeloma
Phase I Study of BB-10901 (huN901-DM1) in Patients with Relapsed/Refractory CD56-Positive Myeloma
Phase I/II Study of a Combination of Velcade, Melphalan, Prednisone, and Thalidomide (VMPT) for Relapsed Myeloma
Phase I/II Study of Oral Cyclophosphamide, Prednisone, and Velcade in Patients with Relapsed/Refractory Myeloma
Phase III International Randomized Study of Velcade vs Velcade/Doxil in Relapsed/Refractory Myeloma
Revlimid in Combination with Dex is More Effective than Dexamethasone Alone at First Relapse
A Phase I Study of HCD122 (formerly CHIR1212), a Monoclonal Antibody to CD40, in Relapsed/Refractory Myeloma
A Retrospective Study of the Significance of Complete Response (CR) on Outcomes in Myeloma Treatment
Mi-63, a Small Molecule Inhibitor of MDM2-p53 Interaction, Has Significant In Vitro Activity in Multiple Myeloma
New Proteasome Inhibitor NPI-0052
Phase I Study of KOS-953 + Velcade in Patients with Relapsed/Refractory MM
SNP Association with Event-Free Survival (EFS) in Myeloma from Two Phase III Trials Using the Bank On A Cure SNP Chip
The Effect of Genetically Modified Measles Virus on Myeloma Cells in Vitro
The Genetic Contribution to the Etiology of Thalidomide-Associated VTE
A Phase I/II Study of Consolidation Therapy with Velcade after Tandem Transplant
A Phase II Study of Alternating Velcade and Dexamethasone as Induction Therapy Prior to Transplant in Newly Diagnosed Patients
A Retrospective Analysis of High Dose Therapy in Patients with Renal Insufficiency
A Retrospective Analysis of the Significance of Measurable Disease at Time of Transplant
A Retrospective Analysis of Three Induction Regimens for Newly Diagnosed Myeloma Prior to Transplant
A Retrospective Study of the Significance of VGPR/CR in the IFM 99 Trials
An Analysis of Response Criteria Post-Stem Cell Transplant in AL Amyloidosis
An Interim Analysis of Velcade/Dexamethasone vs VAD as Induction Therapy Prior to Transplant in Newly Diagnosed Myeloma
Prospective Randomized Comparison of Double Transplant with Melphalan 200 vs Triple Transplant with Melphalan 100
Velcade Added to High-Dose Cytoxan and GCSF as a Mobilization Regimen for Stem Cell Collection Prior to HDT
ASH Overview
|
|
|
The IMF went to ASH and asked several key participants for their views of this important meeting. The overviews are in English, Turkish, Czech, Spanish, French, and German.
|
|
|
Overview of ASH 2006 in Czech
|
|
|
|
Prof. Roman Hájek
Masaryk University
Brno, Czech Republic
|
|
|
|
|
Hartmut Goldschmidt, MD
Universitätsklinikum Heidelberg (University Clinic of Heidelberg) und Nationales Centrum für Tumorerkrankungen (and the National Center of Tumor Diseases)
Heidelberg, Deutschland
|
|
|
|
|
Dina Ben-Yehuda, MD
Hadassah University Hospital
Jerusalem, Israel
|
|
Novel Agents - Newly-Diagnosed Myeloma
|
|
|
S. Vincent Rajkumar, MD
Mayo Clinic
Rochester, MN
|
|
|
|
|
|
S. Vincent Rajkumar, MD
Mayo Clinic
Rochester, MN
|
|
|
|
|
Jesús San Miguel, MD
Hospital Clinico Universitario
Universidad de Salamanca
Salamanca, Spain
|
|
|
|
|
Asher A. Chanan-Khan, MD
Roswell Park Cancer Institute
Buffalo, NY
|
|
|
|
|
Ruben Niesvizky, MD
New Presbyterian Hospital
Weill Cornell Medical Center
New York, NY
|
|
|
|
|
A. Keith Stewart, MD
Mayo Clinic
Scottsdale, AZ
|
|
|
|
|
Martha Q. Lacy, MD
Mayo Clinic
Rochester, MN
|
|
|
|
|
Sundar Jagannath, MD
St. Vincent’s Comprehensive Cancer Center
New York, NY
|
|
|
|
|
Antonio Palumbo, MD
Ospedale Molinette
Torino, Italy
|
|
|
|
|
|
Ruben Niesvizky, MD
New Presbyterian Hospital
Weill Cornell Medical Center
New York, NY
|
|
|
|
|
|
Ruben Niesvizky, MD
New Presbyterian Hospital
Weill Cornell Medical Center
New York, NY
|
|
|
|
|
Angela Dispenzieri, MD
Mayo Clinic
Rochester, MN
|
|
|
|
|
|
Jesús San Miguel, MD
Hospital Clinico Universitario
Universidad de Salamanca
Salamanca, Spain
|
|
|
|
|
|
Angela Dispenzieri, MD
Mayo Clinic
Rochester, MN
|
|
|
|
|
Donna E. Reece, MD
Princess Margaret Hospital
Toronto, Canada
|
|
|
|
|
Robert Z. Orlowski, MD
Lineberger Cancer Center
University of North Carolina
Chapel Hill, NC
|
|
Novel Agents - Relapsed/Refractory Myeloma
|
|
|
Stefan Knop, MD
Universitätsklinikums Würzburg (University Clinic of Wuerzburg)
Würzburg, Germany
|
|
|
|
|
|
Asher A. Chanan-Khan, MD
Roswell Park Cancer Institute
Buffalo, NY
|
|
|
|
|
Michael Wang, MD
MD Anderson Cancer Center
Houston, Texas USA
|
|
|
|
|
Heinz Ludwig, MD
Wilhelminenspital der Stadt Wein
Vienna, Austria
|
|
|
|
|
Paul G. Richardson, MD
Dana Farber Cancer Institute
Boston, Massachusetts USA
|
|
|
|
|
|
Asher A. Chanan-Khan, MD
Roswell Park Cancer Institute
Buffalo, NY
|
|
|
|
|
|
Antonio Palumbo, MD
Ospedale Molinette
Torino, Italy
|
|
|
|
|
|
Donna E. Reece, MD
Princess Margaret Hospital
Toronto, Canada
|
|
|
|
|
|
Robert Z. Orlowski, MD
Lineberger Cancer Center
University of North Carolina
Chapel Hill, NC
|
|
|
|
|
Edward A. Stadtmauer, MD
Hospital of the University of Pennsylvania
Philadelphia, PA
|
|
New Agents and Approaches
|
|
|
William Bensinger, MD
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, WA
|
|
|
|
|
|
Michael Wang, MD
MD Anderson Cancer Center
Houston, Texas USA
|
|
|
|
|
Shaji Kumar, MD
Mayo Clinic
Rochester, MN
|
|
|
|
|
Michael Palladino, PhD
Nereus Pharmaceuticals
San Diego, CA
|
|
|
|
|
|
Paul G. Richardson, MD
Dana Farber Cancer Institute
Boston, Massachusetts USA
|
|
|
|
|
Brian Van Ness, PhD
University of Minnesota
Institute of Human Genetics
Minneapolis, MN
|
|
|
|
|
Hermann Einsele, MD
Universitätsklinikums Würzburg (University Clinic of Wuerzburg)
Würzburg, Germany
|
|
|
|
|
Gareth Morgan, MD
The Royal Marsden Hospital
Sutton, Surrey, UK
|
|
Transplantation
|
|
|
|
Hermann Einsele, MD
Universitätsklinikums Würzburg (University Clinic of Wuerzburg)
Würzburg, Germany
|
|
|
|
|
|
Jesús San Miguel, MD
Hospital Clinico Universitario
Universidad de Salamanca
Salamanca, Spain
|
|
|
|
|
|
Shaji Kumar, MD
Mayo Clinic
Rochester, MN
|
|
|
|
|
|
Shaji Kumar, MD
Mayo Clinic
Rochester, MN
|
|
|
|
|
|
Shaji Kumar, MD
Mayo Clinic
Rochester, MN
|
|
|
|
|
Jean-Luc Harousseau, MD
Hematologie Clinique
CHU Hotel Dieu
Nantes, France
|
|
|
|
|
Morie Gertz, MD
Mayo Clinic
Rochester, MN
|
|
|
|
|
|
Jean-Luc Harousseau, MD
Hematologie Clinique
CHU Hotel Dieu
Nantes, France
|
|
|
|
|
|
Heinz Ludwig, MD
Wilhelminenspital der Stadt Wein
Vienna, Austria
|
|
|
|
|
|
Ruben Niesvizky, MD
New Presbyterian Hospital
Weill Cornell Medical Center
New York, NY
|
|
|
back
print
related articles
Be the first to comment